Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ]: Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ]: Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012
Thu, June 28, 2012
Wed, June 27, 2012
Tue, June 26, 2012

Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. at-the-jmp-securities-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference -- SAN DIEGO, July 9, 2012 /PRNewswire/ --

Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference

[ ]

SAN DIEGO, July 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]) today announced that management will present a company overview at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Thursday, July 12th at 3:00 p.m. EDT. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at [ www.orexigen.com ]. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at [ www.orexigen.com ].

Orexigen Contact:

Media Contact: 

McDavid Stilwell

Denise Powell

VP, Corporate Communications and Business Development

WCG

(858) 875-8629

(510) 703-9491

SOURCE Orexigen Therapeutics, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.orexigen.com ]


Publication Contributing Sources